229 related articles for article (PubMed ID: 38340237)
41. Dual inhibition of IL-17A and IL-17F in psoriatic disease.
Iznardo H; Puig L
Ther Adv Chronic Dis; 2021; 12():20406223211037846. PubMed ID: 34408825
[TBL] [Abstract][Full Text] [Related]
42. Management of Plaque Psoriasis With Biologic Therapies in Women of Child-Bearing Potential Consensus Paper.
Yeung J; Gooderham MJ; Grewal P; Hong CH; Lansang P; Papp KA; Poulin Y; Turchin I; Vender R
J Cutan Med Surg; 2020; 24(1_suppl):3S-14S. PubMed ID: 32500730
[TBL] [Abstract][Full Text] [Related]
43. Emerging treatment options for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis: evaluating bimekizumab and its therapeutic potential.
Chiricozzi A; De Simone C; Fossati B; Peris K
Psoriasis (Auckl); 2019; 9():29-35. PubMed ID: 31214486
[TBL] [Abstract][Full Text] [Related]
44. Ultraviolet Phototherapy Management of Moderate-to-Severe Plaque Psoriasis: An Evidence-Based Analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2009; 9(27):1-66. PubMed ID: 23074532
[TBL] [Abstract][Full Text] [Related]
45. Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis: Pooled Results From Phase 2 and Phase 3 Randomized Clinical Trials.
Gordon KB; Langley RG; Warren RB; Okubo Y; Stein Gold L; Merola JF; Peterson L; Wixted K; Cross N; Deherder D; Thaçi D
JAMA Dermatol; 2022 Jul; 158(7):735-744. PubMed ID: 35544084
[TBL] [Abstract][Full Text] [Related]
46. Bimekizumab for the Treatment of Plaque Psoriasis with Involvement of Genitalia: A 16-Week Multicenter Real-World Experience - IL PSO (Italian Landscape Psoriasis).
Orsini D; Malagoli P; Balato A; Bianchi L; Brianti P; Buononato D; Burlando M; Caldarola G; Campanati A; Campione E; Carrera CG; Carugno A; Cusano F; Dapavo P; Dattola A; De Simone C; Dini V; Esposito M; Fargnoli MC; Gaiani FM; Gargiulo L; Gisondi P; Giunta A; Ibba L; Lasagni C; Loconsole F; Maione V; Mortato E; Marzano AV; Maurelli M; Megna M; Mercuri SR; Narcisi A; Offidani A; Paolino G; Parodi A; Pellacani G; Potestio L; Quaglino P; Richetta AG; Romano F; Sena P; Venturini M; Assorgi C; Costanzo A
Dermatol Pract Concept; 2024 Apr; 14(2):. PubMed ID: 38416060
[TBL] [Abstract][Full Text] [Related]
47. Successful Treatment with Bimekizumab of a Psoriatic Patient Undergoing Hemodialysis: A Case Report and Review of the Literature.
Bernardini N; Ambrosio L; Tolino E; Proietti I; Skroza N; Potenza C
J Clin Med; 2024 Apr; 13(8):. PubMed ID: 38673523
[No Abstract] [Full Text] [Related]
48. Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial.
Ritchlin CT; Kavanaugh A; Merola JF; Schett G; Scher JU; Warren RB; Gottlieb AB; Assudani D; Bedford-Rice K; Coarse J; Ink B; McInnes IB
Lancet; 2020 Feb; 395(10222):427-440. PubMed ID: 32035552
[TBL] [Abstract][Full Text] [Related]
49. Psoriasis beyond the skin: an expert group consensus on the management of psoriatic arthritis and common co-morbidities in patients with moderate-to-severe psoriasis.
Strohal R; Kirby B; Puig L; ; Girolomoni G; Kragballe K; Luger T; Nestle FO; Prinz JC; Ståhle M; Yawalkar N
J Eur Acad Dermatol Venereol; 2014 Dec; 28(12):1661-9. PubMed ID: 24372845
[TBL] [Abstract][Full Text] [Related]
50. Comparative efficacy and safety of bimekizumab in psoriatic arthritis: a systematic literature review and network meta-analysis.
Mease PJ; Gladman DD; Merola JF; Nash P; Grieve S; Laliman-Khara V; Willems D; Taieb V; Prickett AR; Coates LC
Rheumatology (Oxford); 2024 Jan; ():. PubMed ID: 38218744
[TBL] [Abstract][Full Text] [Related]
51. Cost-effectiveness analysis of bimekizumab for the treatment of active psoriatic arthritis in Sweden.
Sigurdardottir V; Engstrom A; Berling P; Olofsson T; Oldsberg L; Sadler S; Parra-Padilla D; Melis L; Willems D
J Med Econ; 2023; 26(1):1190-1200. PubMed ID: 37712618
[TBL] [Abstract][Full Text] [Related]
52. Position Statement on Secukinumab in the Management of Plaque Psoriasis: The Malaysian Perspective.
Johar A; Thevarajah S; Heng A; Chan LC; Ch'ng CC; Mohd Safdar NA; Muniandy P; Taib T; Tan WC; Tey KE
Dermatol Res Pract; 2019; 2019():8923168. PubMed ID: 31214257
[TBL] [Abstract][Full Text] [Related]
53. Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial.
Thaçi D; Vender R; de Rie MA; Conrad C; Pariser DM; Strober B; Vanvoorden V; Wang M; Madden C; de Cuyper D; Kimball AB
Br J Dermatol; 2023 Jan; 188(1):22-31. PubMed ID: 36689515
[TBL] [Abstract][Full Text] [Related]
54. An Overview of Bimekizumab for the Treatment of Psoriatic Arthritis: The Evidence so Far.
Oliveira DG; Faria R; Torres T
Drug Des Devel Ther; 2021; 15():1045-1053. PubMed ID: 33727793
[TBL] [Abstract][Full Text] [Related]
55. Formulary review of 2 new biologic agents: tocilizumab for rheumatoid arthritis and ustekinumab for plaque psoriasis.
Schafer JA; Kjesbo NK; Gleason PP
J Manag Care Pharm; 2010; 16(6):402-16. PubMed ID: 20635831
[TBL] [Abstract][Full Text] [Related]
56. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Garcia-Doval I; Do G; Hua C; Mazaud C; Droitcourt C; Hughes C; Ingram JR; Naldi L; Chosidow O; Le Cleach L
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011535. PubMed ID: 29271481
[TBL] [Abstract][Full Text] [Related]
57. Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trials.
Kokolakis G; Warren RB; Strober B; Blauvelt A; Puig L; Morita A; Gooderham M; Körber A; Vanvoorden V; Wang M; de Cuyper D; Madden C; Nunez Gomez N; Lebwohl M
Br J Dermatol; 2023 Feb; 188(3):330-340. PubMed ID: 36751950
[TBL] [Abstract][Full Text] [Related]
58. Ixekizumab for the treatment of psoriasis: an update on new data since first approval.
Blegvad C; Skov L; Zachariae C
Expert Rev Clin Immunol; 2019 Feb; 15(2):111-121. PubMed ID: 30589394
[No Abstract] [Full Text] [Related]
59. Treatment of Severe Palmoplantar Pustular Psoriasis With Bimekizumab.
Passeron T; Perrot JL; Jullien D; Goujon C; Ruer M; Boyé T; Villani AP; Quiles Tsimaratos N
JAMA Dermatol; 2024 Feb; 160(2):199-203. PubMed ID: 38054800
[TBL] [Abstract][Full Text] [Related]
60. Rapid response on facial psoriasis to bimekizumab: case series.
Bernardini N; Dattola A; Caldarola G; Orsini D; Assorgi C; D'Amore A; Maretti G; Richetta AG; Tolino E; Skroza N; Potenza C
Drugs Context; 2024; 13():. PubMed ID: 38817804
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
